Rua Life Sciences Plc · LSE:RUA
Rua Life Sciences — FY2025 Earnings Presentation
23 slides from Rua Life Sciences's earnings presentation, Jul 8, 2025
Slide 1: Second Interim (12 Month) results to 31 March 2025 and Business Update
Second Interim (12 Month) results to 31 March 2025 and Business Update Bill Brown, CEO Lachlan Smith, CFO 08 July 2025 1 INNOVATING TO ENHANCE LIVES
Slide 2: Company Overview
COMPANY OVERVIEW IMPROVING AND ENABLING MEDICAL DEVICES Revenue Generation IP Developed for exploitation BIOMATERIALS MEDICAL DEVICES AND VASCULAR STRUCTURAL HEART COMPONENTS The Home of our platform technology Offers expert design, development Elast-Eon enabled vascular grafts. Elast-Eon enabled co
Slide 3: Group Financials
RUA\| sciences | GROUP FINANCIALS N
Slide 4: Consolidated Income Statement
Consolidated Income Statement Minimal increase (10%) in Group Revenue £4.1m increase Administrative costs of £0.4m of £1.9m (2024: £2.2m) from £3.8m to £4.2m Group GM remains high at 77% £0.9m Gain on Bargain purchase (2024: 81%) on Acquisition of ABISS Year to: Mar-25 Mar-24 £’000s £’000s Revenue 4
Slide 5: RUA Biomaterials
RUA Biomaterials Royalty and license fee income £587k Increased supply of Elast-Eon (1,744lbs) up increased by 18% (£496k FY24) 18% (1,478lbs FY24) 80% + of 2025 – 2026 covered by existing High Gross Margin at 95% (90% FY24) licensee order book Year to: Mar-25 Mar-24 £’000s £’000s Revenue 587 496 Co
Slide 6: Medical Devices and Components
Medical Devices and Components Contract Manufacturing income £3,526k 90% of 2025 – 2026 covered by existing order increased by 108% (£1,679k FY24) book High Gross Margin at 73% (75% FY24) Acquisition of ABISS Group Year to: Mar-25 Mar-24 £’000s £’000s Revenue 3,526 1,679 Cost of Sales (941) (415) Gr
Slide 7: Reconciliation of Losses
Reconciliation of Losses “Controlling costs and securing new business are essential strategies to meet our objectives of reaching profitability” Year to: Mar-25 Mar-24 £’000s £’000s EBITDA excluding Gain on Bargain Purchase (516) (1,573) Gain on Bargain purchase 917 - EBITDA 401 (1,573) Depreciation
Slide 8: Consolidated Financial Position
Consolidated Financial Position Strengthened balance sheet £67k bought £1.0m of net assets Cash at £3.6m £0.6m WIP & Finished Goods Year to: Mar-25 Mar-24 £’000s £’000s Non-Current Assets 3,842 3,176 Cash and Equivalents 3,567 3,931 Other Current Assets 1,846 1,062 Total Assets 9,255 8,169 Total Lia
Slide 9: Cashflow Headlines
Cashflow Headlines Cash at £3.6m Reduction in borrowings £0.2m Operational cash flows (0.2m) Positive net cash flow from consumed are £1.1m less than investing activities of £0.1m FY2024 (1.3m) Year to: Mar-25 Mar-24 £’000s £’000s Net cash inflow from operating activities (219) (1,328) Net cash outf
Slide 10: Operational Performance
OPERATIONAL PERFORMANCE “…We are pleased with the group's performance and are planning to increase capacity across all our businesses.”
Slide 11: Biomaterials: The worlds leading biostable polyurethanes
Biomaterials The worlds leading biostable polyurethanes Elast-Eon™ and ECSil™ two of the most biostable and non-thrombogenic of all polyurethane materials, they improve the performance and durability of medical devices, reducing the need for future interventions. Properties Uses Biostable Neurostimu
Slide 12: Biomaterials Focus & Priorities
Biomaterials Focus & Priorities Strategic Improved partnering Marketing Increase focus Long term on license deals planning 12 INNOVATING TO ENHANCE LIVES image: Freepik.com
Slide 13: Biomaterials Strategic Refocus Driving Growth
Biomaterials Strategic Refocus Driving Growth Strategic shift • Refocused into high-potential business segments • Prioritised Biomaterials as core value driver Execution • Strengthened engagement with partners • Expanded marketing and outreach activities • Increased business development across new t
Slide 14: Medical Devices & Components: End to end contract developer and manufacturer
Medical Devices & Components End to end contract developer and manufacturer of medical devices RUA Medical is a medical textiles ad implantable fabric specialist contract manufacturer and holds ISO 13485:2016 certification. We occupy two FDA registered facilities. Works with a number of businesses i
Slide 15: Medical Devices & Components Building Value
Medical Devices & Components Building Value Strategic refocus • Acquired ABISS for £67k, gaining control of £1.0m in assets • Repositioned as a growth platform within our Group • Complements our high-margin licensing and biomaterials strategy Early commercial success • Customer growth one key accoun
Slide 16: Growth opportunity: Addressing high growth markets
Growth opportunity Addressing high growth markets MARKET USD 149bn Global medical device Growth rate: manufacturing market is Challenge: CAGR 11.4% expected to be worth Lack of $149b by 2029 innovation Driver: Opportunity: Rising aging population Growth in Restraint: emerging Stringent countries reg
Slide 17: ABISS Acquisition
RUA\| sciences | ABISS ACQUISITION N
Slide 18: ABISS - Acquisition
ABISS - Acqusition • Core of implantable textiles • Own CE Mark Products • Product and IP portfolio • Coloplast licensee/distributor • FDA registered facility in St Etienne • ISO 13485 facility • Clean room production • Regulatory, clinical and QMS • Talented team • Contract Manufacture business • O
Slide 19: Locations
Locations 19 INNOVATING TO ENHANCE LIVES
Slide 20: Business Outlook
RUA\| sciences | BUSINESS OUTLOOK N
Slide 21: Summary
Summary IMPROVING AND ENABLING MEDICAL DEVICES Group revenue growing through strong customer relationships Underlying profit improvement from cash generating units Strong product pipeline across all segments Composite leaflet material exceeding expectations Well advanced to commercialise vascular Ef
Slide 22: Pathway to Create Long-Term Shareholder Value
PATHWAY TO CREATE LONG-TERM SHAREHOLDER VALUE STRATEGY ACCELERATION Stimulate revenue expansion and drive growth across segments Allocate investments towards streamlining processes and systems Achieve enhanced profit margins by boosting productivity Strategically reorganise the contract manufacturin
Slide 23: Thank you
Thank you 23 INNOVATING TO ENHANCE LIVES